Ji X - Search Results

1

Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients.

Deng Q, Xie B, Wu L, Ji X, Li C, Feng L, Fang Q, Bao Y, Li J, Jin S, Ding C, Li Y, Zhou S. Deng Q, et al. Among authors: ji x. Heliyon. 2018 Dec 19;4(12):e01031. doi: 10.1016/j.heliyon.2018.e01031. eCollection 2018 Dec. Heliyon. 2018. PMID: 30603682 Free PMC article.

2

Overexpression of miR-100 inhibits cancer growth, migration, and chemosensitivity in human NSCLC cells through fibroblast growth factor receptor 3.

Luo J, Chen B, Ji XX, Zhou SW, Zheng D. Luo J, et al. Tumour Biol. 2015 Aug 28. doi: 10.1007/s13277-015-3850-z. Online ahead of print. Tumour Biol. 2015. PMID: 26314855 Free article.

3

SPOP promotes SIRT2 degradation and suppresses non-small cell lung cancer cell growth.

Luo J, Bao YC, Ji XX, Chen B, Deng QF, Zhou SW. Luo J, et al. Biochem Biophys Res Commun. 2017 Feb 5;483(2):880-884. doi: 10.1016/j.bbrc.2017.01.027. Epub 2017 Jan 7. Biochem Biophys Res Commun. 2017. PMID: 28073696

4

Corrigendum to "SPOP promotes SIRT2 degradation and suppresses non-small cell lung cancer cell growth" [Biochem. Biophys. Res. Commun. 483 (2017) 880-884].

Luo J, Bao YC, Ji XX, Chen B, Deng QF, Zhou SW. Luo J, et al. Biochem Biophys Res Commun. 2017 Apr 22;486(1):57. doi: 10.1016/j.bbrc.2017.02.122. Epub 2017 Mar 11. Biochem Biophys Res Commun. 2017. PMID: 28292429 No abstract available.

5

Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy.

Deng Q, Su B, Ji X, Fang Q, Zhou S, Zhou C. Deng Q, et al. Among authors: ji x. Cancer Biomark. 2020;27(3):313-323. doi: 10.3233/CBM-190258. Cancer Biomark. 2020. PMID: 31839603

6

Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis.

Deng QF, Fang QY, Ji XX, Zhou SW. Deng QF, et al. J Cancer. 2020 Mar 26;11(12):3667-3674. doi: 10.7150/jca.42850. eCollection 2020. J Cancer. 2020. PMID: 32284763 Free PMC article.

7

DNMT3A governs tyrosine kinase inhibitors responses through IAPs and in a cell senescence-dependent manner in non-small cell lung cancer.

Deng QF, Li C, Liu J, Ji XX, Wan XY, Wang CY, Sun H, Fang QY, Gu WQ, Ma C, Wang HY, Zhou CC, Li YX, Xie BX, Zhou SW. Deng QF, et al. Am J Cancer Res. 2023 Aug 15;13(8):3517-3530. eCollection 2023. Am J Cancer Res. 2023. PMID: 37693159 Free PMC article.

8

METTL14 enhances the m6A modification level of lncRNA MSTRG.292666.16 to promote the progression of non-small cell lung cancer.

Ji X, Wan X, Sun H, Deng Q, Meng S, Xie B, Zhou S. Ji X, et al. Cancer Cell Int. 2024 Feb 7;24(1):61. doi: 10.1186/s12935-024-03250-3. Cancer Cell Int. 2024. PMID: 38326804 Free PMC article.

9

Different clinical features between patients with ROS1-positive and ALK-positive advanced non-small cell lung cancer.

Ji X, Xie H, Zhu R, Chen B, Jiang S, Luo J. Ji X, et al. J Int Med Res. 2021 Feb;49(2):300060521993643. doi: 10.1177/0300060521993643. J Int Med Res. 2021. PMID: 33583243 Free PMC article.

10

HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies.

Yu X, Ji X, Su C. Yu X, et al. Among authors: ji x. Front Oncol. 2022 Mar 29;12:860313. doi: 10.3389/fonc.2022.860313. eCollection 2022. Front Oncol. 2022. PMID: 35425713 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9,894 results

Search Page

Filters